Join

Compare · NVO vs PYPD

NVO vs PYPD

Side-by-side comparison of Novo Nordisk A/S (NVO) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and PYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $220.35B, about 2610.6x PYPD ($84.4M).
  • NVO has been more active in the news (5 items in the past 4 weeks vs 3 for PYPD).
  • NVO has more recent analyst coverage (25 ratings vs 6 for PYPD).
MetricNVOPYPD
Company
Novo Nordisk A/S
PolyPid Ltd.
Price
-
-
Market cap
$220.35B
$84.4M
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
5
3
Recent ratings
25
6
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PYPD

PolyPid Ltd.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Latest NVO

Latest PYPD